TET2 and CD4+/CD56+ hematodermic neoplasm: Their findings support the hypothesis that TET2 and ASXL1 mutations may represent early events in BPDCN pathogenesis, while additional mutations are likely acquired secondarily through genomic instability and clonal evolution driven by epigenetic dysregulation.